Lifileucel
Lifileucel is an investigational immunotherapy treatment designed for patients with advanced melanoma. It is a type of adoptive cell transfer (ACT) therapy that utilizes tumor-infiltrating lymphocytes (TILs) to target and destroy cancer cells.
Mechanism of Action[edit | edit source]
Lifileucel works by harnessing the body's own immune system to fight cancer. The process begins with the extraction of TILs from a patient's tumor. These TILs are then expanded and activated in a laboratory setting before being reintroduced into the patient's body. Once administered, the TILs seek out and attack cancer cells, leveraging their natural ability to recognize and destroy malignant cells.
Clinical Development[edit | edit source]
Lifileucel is currently undergoing clinical trials to evaluate its safety and efficacy. Early-phase studies have shown promising results, with some patients experiencing significant tumor reduction. The therapy is being developed by Iovance Biotherapeutics, a company specializing in TIL-based therapies.
Administration[edit | edit source]
The administration of Lifileucel involves several steps: 1. **Tumor Harvesting**: A sample of the patient's tumor is surgically removed. 2. **TIL Expansion**: The TILs are isolated from the tumor sample and expanded in a laboratory. 3. **Preconditioning**: The patient undergoes a lymphodepleting regimen to prepare the body for the infusion of TILs. 4. **TIL Infusion**: The expanded TILs are infused back into the patient. 5. **Post-Infusion Care**: The patient may receive supportive care and monitoring to manage any side effects.
Potential Side Effects[edit | edit source]
As with any immunotherapy, Lifileucel may cause side effects. Common side effects include fever, chills, fatigue, and cytokine release syndrome (CRS). More severe side effects can occur and require careful monitoring and management by healthcare professionals.
Future Directions[edit | edit source]
Research is ongoing to explore the potential of Lifileucel in treating other types of cancer beyond melanoma. Additionally, combination therapies involving Lifileucel and other immunotherapies or targeted treatments are being investigated to enhance its efficacy.
Related Pages[edit | edit source]
- Immunotherapy
- Melanoma
- Adoptive cell transfer
- Tumor-infiltrating lymphocytes
- Iovance Biotherapeutics
- Cytokine release syndrome
References[edit | edit source]
External Links[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
